Probiotics: do they help to control intestinal inflammation?
There is currently a growing appreciation for the role of the enteric flora in health and disease. In the past years overwhelming evidence has accumulated for the role of commensal gut bacteria in the inflammatory bowel diseases Crohn's disease and ulcerative colitis. Both entities are mainly located in areas with high bacterial concentrations. Reduction of the enteric bacterial concentration by antibiotics, lavage, or surgical bypass results in a mitigation of symptoms, while experimental colitis models depend on the presence of the bacterial flora and the NOD2/CARD15-mutation results in inefficient clearance of invasive bacteria. Those findings helped to bring the concept of probiotic therapy to the forefront, a therapy that had been known for millennia, but had been disregarded by the scientific world. Probiotics are meanwhile established in the maintenance therapy of ulcerative colitis and chronic recurrent or refractory pouchitis. Promising data exist for the primary prevention of pouchitis. Probiotic research at the intersection of gastroenterology, immunology and microbiology is highly dynamic in both the basic and the clinical field. Further understanding of the complex molecular mechanisms leading to the effectiveness of probiotics will also spur the development of more successful probiotic formulations.
Böhm
S K
SK
Evangelisches Krankenhaus Kalk, Abteilung für Innere Medzin, Universität Zu Köln, Buchforststrasse 2, Köln, Germany. boehm@evkk.de
Kruis
W
W
D000818:Animals; D003093:Colitis, Ulcerative / Q000517:prevention & control / Q000628:therapy; D003424:Crohn Disease / Q000517:prevention & control / Q000628:therapy; D004195:Disease Models, Animal; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000517:prevention & control* / Q000628:therapy; D019936:Probiotics / Q000627:therapeutic use*; D012074:Remission Induction; D015203:Reproducibility of Results